LINDIS Biotech Consolidates Onco-Immune, Trifunctional, Bispecific Antibody IP and Know-How from TRION Pharma

Horst Lindhofer, CEO of LINDIS Biotech and inventor of the trifunctional antibody technology succeeded in regaining the relevant IP and know-how from TRION Pharma out of the insolvency proceedings. Currently, LINDIS consolidates these patents and know-how with relevant LINDIS IP and hosts several advanced trifunctional antibody programs. The company plans to hire a limited number of highly experienced staff to continue clinical development once it has raised additional capital.

Dr Horst Lindhofer explained: “We seek to capitalise the company that now houses a pipeline of three new potential treatments against malignant tumours based on the trifunctional platform. One is in late pre-clinical and two are in Phase I/II clinical stage. The fund-raising comes at a great time given the compelling and positive clinical update of our Lymphomun programme.”

“When the industry converted to human/humanised antibodies, we chose to further develop our murine-based antibody platform due to its vaccination effect and the direct tumour-cell-killing potential that we discovered as early as 1997. Today we are unique because of this special characteristic. Our powerful effects on solid tumours were first verified in 2006,” explained Dr Lindhofer.

“We are grateful to our advisors, IMI Consulting GmbH (IMI) and Partners, for supporting us during the TRION Pharma insolvency process. IMI will now resume the discussions with potential investors for Round A,” Dr Lindhofer further added.

“The trifunctional antibody therapy is a platform that carries the hopes of cancer patients worldwide as it triggers the patient’s own immune system to recognise and destroy the cancer cells and, moreover, to induce a lasting immune memory against the individual mutations of the patient’s tumour cells. These antibodies can easily be adapted to fight many different types of cancers,” added Dr Lindhofer